Research and development can be an intangible asset, but in most cases under U.S. accounting rules, it is not. The default treatment under U.S. GAAP is to expense R&D costs as they are incurred, meaning they hit the income statement immediately rather than appearing on the balance sheet as an asset. International accounting standards (IFRS) take a different approach, allowing companies to capitalize the development phase of R&D once certain conditions are met. The answer depends on which accounting framework applies, whether the R&D was created internally or acquired, and what type of project is involved.
Why Most R&D Is Expensed, Not Capitalized
Under U.S. GAAP, the core rule comes from ASC 730, which requires companies to charge all research and development costs to expense in the period they occur. The logic is straightforward: R&D outcomes are uncertain, and accounting standards generally resist putting uncertain future benefits on the balance sheet. A pharmaceutical company spending millions on a drug that might never reach the market, for example, must record those costs as current expenses rather than building up an intangible asset over time.
This means that for most U.S. companies, R&D never appears as a line item under intangible assets. Instead, financial statements disclose the total R&D costs charged to expense for each reporting period. The spending reduces net income in the year it happens, even if the project could generate revenue for a decade.
When R&D Does Become an Intangible Asset
There are several important exceptions where R&D crosses the line from expense to asset.
Acquired R&D: When one company acquires another, any in-process research and development projects held by the target company get capitalized as intangible assets, separate from goodwill. This has been required since the update to business combination rules under FASB Statement 141(R). So the same R&D project that was being expensed on the acquired company’s books suddenly becomes an intangible asset on the buyer’s balance sheet.
Software development: Software costs follow a split model. All costs incurred before a project reaches a specific milestone are treated as R&D and expensed. For software sold externally, that milestone is “technological feasibility,” the point at which the company has confirmed the product can be built as designed. For internal-use software, FASB recently updated its guidance to require capitalization once management has authorized and committed to funding the project and it is probable the project will be completed. After these thresholds are crossed, costs shift from expense to capitalized intangible asset.
Under IFRS: International Financial Reporting Standards draw a clear line between the research phase (always expensed) and the development phase. Once a project demonstrates technical feasibility, an intention to complete it, the ability to use or sell the result, and reliably measurable costs, those development expenditures are capitalized as intangible assets. This is why companies reporting under IFRS often carry significantly more intangible assets on their balance sheets than comparable U.S. companies.
How Capitalized R&D Appears on Financial Statements
When R&D does qualify for capitalization, it shows up on the balance sheet under intangible assets, sometimes labeled as “capitalized development costs,” “in-process research and development,” or “capitalized software costs.” The asset is then amortized over its useful life, spreading the cost across the income statement over the years the company expects to benefit from it.
Intangible assets that are not yet available for use, such as an R&D project still in progress, receive extra scrutiny. Under IAS 36, these assets must be tested for impairment at least annually, regardless of whether there are signs of trouble. This is the same treatment given to goodwill and intangible assets with indefinite useful lives. The annual test ensures the balance sheet value still reflects reality, since in-progress projects carry more risk of failure than completed ones.
The Tax Side Works Differently
Tax rules and accounting rules don’t always align, and R&D is a prime example. For U.S. tax purposes, the treatment of domestic R&D expenditures recently shifted. For tax years beginning after December 31, 2024, domestic research and experimental expenditures are once again deductible in the year they are paid or incurred. Companies can also elect to capitalize and amortize these costs over a period of at least 60 months if that better suits their tax strategy.
Foreign research expenditures follow a stricter path. They must be capitalized and amortized over 15 years, starting at the midpoint of the tax year in which the spending occurs. This creates a meaningful difference in cash flow timing for companies with global R&D operations.
Why the Classification Matters for Financial Analysis
Whether R&D sits on the income statement or the balance sheet has a real impact on how a company’s finances look to investors and lenders. When R&D is expensed, it reduces reported earnings immediately. A company spending heavily on R&D can look unprofitable even if its projects are on track to generate substantial future revenue.
When R&D is capitalized instead, the effect reverses. Net income rises because the full cost no longer hits the current year’s earnings, and total assets increase because the R&D now sits on the balance sheet. NYU Stern analysis of capitalizing R&D shows this can increase both operating income and book equity by hundreds of millions of dollars for large companies. In one example, treating R&D as a capital expense rather than an operating expense increased operating income by $117 million and added roughly $2.9 billion to the asset side of the balance sheet.
This matters for ratios investors rely on. Return on assets drops when R&D is capitalized (because the asset base grows), while profit margins improve (because current-year expenses shrink). Asset turnover ratios shift as well. Two companies with identical R&D programs can look financially different simply because one reports under IFRS and capitalizes development costs while the other follows U.S. GAAP and expenses everything. Analysts comparing companies across these frameworks often adjust for this difference to get an apples-to-apples picture.
Practical Takeaway
R&D is an intangible asset only when specific accounting conditions are met: the R&D was acquired in a business combination, the project has passed a defined feasibility threshold (particularly for software), or the company reports under IFRS and the development phase criteria are satisfied. For internally generated R&D at U.S. companies outside these exceptions, the spending flows through the income statement and never reaches the balance sheet as an asset. The distinction is not just academic. It shapes reported profits, balance sheet strength, and the financial ratios that drive investment decisions.